General
Preferred name
AMBENONIUM
Synonyms
Ambenonium chloride ()
Ambenonium dichloride ()
Ambenonium (chloride) ()
Ambenonium ion ()
Ambenonium cation ()
Chlorure d'ambenonium ()
Cloruro de ambenonio ()
Mytelase ()
WIN 8077 (chloride) ()
P&D ID
PD009794
CAS
115-79-7
7648-98-8
52022-31-8
Tags
available
drug
Approved by
FDA
First approval
1956
Drug indication
Myasthenia gravis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
Ambenonium exerts its actions against myasthenia gravis by competitive, reversible inhibition of acetylcholinesterase. The disease myasthenia gravis occurs when the body inappropriately produces antibodies against acetylcholine receptors, and thus inhibits proper acetylcholine signal transmission (when acetylcholine binds to acetylcholine receptors of striated muscle fibers, it stimulates those fibers to contract). Ambenonium reversibly binds acetylcholinesterase at the anionic site, which results in the blockage of the site of acetycholine binding, thereby inhibiting acetylcholine hydrolysis and enhancing cholinergic function through the accumulation of acetycholine at cholinergic synpases. Elevated acetylcholine levels lead to facilitates transmission of impulses across the myoneural junction.
DESCRIPTION
Ambenonium is a long-acting cholinesterase inhibitor used as a treatment of myasthenia gravis. The mechanism of Ambenonium is similar to neostigmine.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Cholinesterase inhibitor
(Tocriscreen Total)
DESCRIPTION
EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
18
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
Tocris Bioactive Compound Library
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
44
Molecular Weight
536.27
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
2
Rotatable Bonds
14
Ring Count
2
Aromatic Ring Count
2
cLogP
4.64
TPSA
58.2
Fraction CSP3
0.5
Chiral centers
0.0
Largest ring
6.0
QED
0.27
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Primary Target
Cholinesterases
MOA
Inhibitor
cholinesterase inhibitor
Indication
myasthenia gravis
Target
AChE
Cholinesterase (ChE)
Pathway
Neuronal Signaling
Therapeutic Class
Antiarrhythmic Agents
Source data
